Noile-Immune Biotech Inc. (TYO:4893)

Japan flag Japan · Delayed Price · Currency is JPY
150.00
-3.00 (-1.96%)
May 12, 2026, 3:30 PM JST
Market Cap6.50B +9.5%
Revenue (ttm)5.00M -28.6%
Net Income-793.00M
EPS-18.31
Shares Out43.30M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume112,900
Average Volume207,360
Open154.00
Previous Close153.00
Day's Range150.00 - 154.00
52-Week Range126.00 - 217.00
Beta0.09
RSI48.49
Earnings DateMay 14, 2026

About Noile-Immune Biotech

Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company’s product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 23
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4893
Full Company Profile

Financial Performance

In 2025, Noile-Immune Biotech's revenue was 5.00 million, a decrease of -28.57% compared to the previous year's 7.00 million. Losses were -793.00 million, -17.74% less than in 2024.

Financial Statements